Sanofi Rilzabrutinib, a new drug for plate reduction, is eligible for FDA fast track

ITP is characterized by immunometric plateplate damage and plate production damage, which leads to reduced downstream plateplates, susceptible bleeding, and affects the quality of life of patients.
current ITP treatment is divided into first- and second-line treatment.
-line treatment usually uses glucoglotin, intravenous C globulin, and anti-D-immunoglobulin, although effective in the short term, but with many side effects.
treatment options are not perfect and there are risks.
, there are still unsolved clinical needs in ITP to provide rapid, lasting relief to patients who relapse or resist after corticosteroid treatment.
BTK belongs to the non-subject tyrosine kinase Tec family and plays an important regulatory role in the differentiation and development of B cells as a key kinase in the signaling path of B cells( BCR).
studies have shown that a large number of expressions of BTK can make the BCR signaling pathline abnormally activated, so that B cell dysfunction, immune tolerance changes, and into autoreactive B cells, secreting a large number of autoantibodies induced autoimmune diseases.
Rilzabrutinib is an oral, reversible, co-priced BTK inhibitor in clinical studies used to treat immuno-mediated diseases.
data show that Rilzabrutinib blocks inflammatory immune cells, eliminates damaging signals from autoantibodies, and prevents the production of new autoantibodies without consuming B cells.
addition, Rilzabrutinib has the potential to target the pathogenesis of potential diseases and has not yet been shown to alter plateplate aggregation.
clinical significance of these mechanisms is currently under study and their safety and importance have not yet been reviewed by any regulatory body.
In terms of ITP therapeutic drugs, Nplate (romiplostim) is the first FDA-approved drug to treat ITP, a platealine-producing analog peptide that opens up new avenues for long-term treatment of this chronic disease by increasing and maintaining plateplate concentrations.
In addition to being approved in the United States, Nplate has also been approved in the European Union for ITP adult patients and for ITP patients 1 year and older who have been under-responding to corticosteroids, immunoglobulin or spleen excisions for at least 6 months.
, Nplate has been ratified by more than 100 countries worldwide.
drug approved by the FDA for the treatment of ITP is GlaxoSmithKline's (GSK) promacta (eltrombopag), a non-peptide oral platelet-producing receptor agonist (TPO-RA) that interacts with the cross-membrane domain of TPO receptors, increasing platelet production and rapidly increasing platelet levels in ITP patients.
is used to treat plate reduction in patients with glucodermal hormone drugs, ineffective immunoglobulin therapy, or chronic primary immunoploid reduction after spleen excision.
the drug will be available in China in 2018.
with the increasing number of ITP treatment drugs, it is bound to provide ITP patients with more treatment options and better treatment experience for patients.
References: